Overview

• On July 30, Servier and BC Partners began exclusive negotiations for Biogaran, nearly a year after Servier suspended its first sale process.
• The bid values the generics leader at between €800 million and €1 billion, consistent with last year’s offer.
• Biogaran accounts for one in three generic medicines sold in France and underpins critical domestic supply chains.
• Bpifrance’s participation in the bid aims to address health sovereignty concerns and streamline regulatory clearance.
• The divestiture underlines Servier’s strategic pivot away from low-margin generics toward innovative treatments in rare diseases, oncology, and neurology.